ELYM · Eliem Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.37M | - | $9.07M | $6.58M | $17.33M | - | $6.09M | $1.05M | $1.09M | - |
| SG&A | $5.84M | - | $5.82M | $4.10M | $5.69M | - | $5.49M | $3.67M | $1.91M | - |
| Total Operating Expenses | $15.21M | - | $14.89M | $10.68M | $23.02M | - | $11.73M | $56.37M | $3.00M | - |
| D&A | $0 | - | - | - | - | - | - | - | - | - |
| Operating Income | ($15.21M) | - | ($14.89M) | ($10.68M) | ($23.02M) | - | ($11.73M) | ($56.37M) | ($3.00M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | $0 | - | $0 | - | - | - |
| Net Income | ($13.72M) | - | ($12.89M) | ($8.67M) | ($20.78M) | - | ($8.89M) | ($54.89M) | ($1.70M) | - |
| EPS - Basic | ($0.20) | - | ($0.19) | ($0.13) | ($0.31) | - | ($0.13) | ($1.81) | ($0.06) | - |
| EPS - Diluted | ($0.20) | - | ($0.19) | ($0.13) | ($0.31) | - | ($0.13) | ($1.81) | ($0.06) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.36M | $35.69M | $25.80M | $22.68M | $29.02M | $87.23M | $146.18M | $223.14M | $105.03M | $93.11M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $860.0K | $2.27M | $477.0K | $946.0K | $777.0K | $705.0K | $291.0K | $509.0K | $85.0K | $66.0K |
| Current Assets | $113.40M | $105.85M | $90.96M | $87.38M | $100.28M | $154.87M | $197.61M | $226.00M | $109.22M | $110.25M |
| Total Assets | $152.37M | $167.74M | $182.30M | $192.39M | $200.74M | $217.19M | $222.20M | $226.02M | $109.33M | $110.47M |
| Current Liabilities | $4.07M | $6.98M | $4.95M | $6.21M | $7.04M | $4.93M | $3.42M | $3.74M | $2.95M | $2.83M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.29M | $7.27M | $5.30M | $6.62M | $7.36M | $5.31M | $3.42M | $3.74M | $2.95M | $2.87M |
| Stockholders' Equity | $148.09M | $160.47M | $177.00M | $185.76M | $193.38M | $211.88M | $218.78M | $222.28M | $106.38M | $107.60M |
| Retained Earnings | ($303.45M) | ($289.73M) | ($272.21M) | ($259.32M) | ($250.66M) | ($229.88M) | ($221.46M) | ($212.56M) | ($157.68M) | ($155.98M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.38M) | - | - | - | ($15.43M) | - | - | - | ($1.82M) | - |
| Investing Cash Flow | ($12.96M) | - | - | - | ($42.75M) | - | - | - | $13.75M | - |
| Financing Cash Flow | $5.0K | - | - | - | $0 | - | - | - | $15.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -9.0% | - | -7.1% | -4.5% | -10.4% | - | -4.0% | -24.3% | -1.6% | - |
| Return on equity | -9.3% | - | -7.3% | -4.7% | -10.7% | - | -4.1% | -24.7% | -1.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 27.86 | 15.16 | 18.38 | 14.08 | 14.25 | 31.41 | 57.73 | 60.41 | 37.02 | 38.92 |
| Quick ratio | 27.86 | 15.16 | 18.38 | 14.08 | 14.25 | 31.41 | 57.73 | 60.41 | 37.02 | 38.92 |
| Cash ratio | 2.05 | 5.11 | 5.21 | 3.66 | 4.12 | 17.69 | 42.70 | 59.65 | 35.60 | 32.87 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.03 | 1.05 | 1.03 | 1.04 | 1.04 | 1.03 | 1.02 | 1.02 | 1.03 | 1.03 |
| Liabilities / Assets | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 33.9% | - | -26.9% | 81.1% | -666.0% | - | -134.6% | -739.6% | 87.2% | - |
| Net income growth (YoY) | 34.0% | - | -44.9% | 84.2% | -1124.6% | - | -124.2% | -951.5% | 92.4% | - |
| EPS growth (YoY) | 35.5% | - | -46.2% | 92.8% | -416.7% | - | 13.3% | -852.6% | 92.9% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -23.4% | -24.3% | -19.1% | -16.4% | 81.8% | 96.9% | 99.4% | 97.6% | -9.0% | -16.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Eliem Therapeutics against the 5 most active filers in the same SIC group.